Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05602025 · ClinicalTrials.gov registry record · Phase 1
A Study to Compare the Pharmacokinetics (PK) of Depemokimab When Delivered With a Safety Syringe Device (SSD) or an Autoinjector in Healthy Adult Participants
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 140
- Enrollment target
NCT05602025 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 140 participants.
The verdict
NCT05602025, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 140 participants
- Enrollment target
Study Summary
This study will compare the pharmacokinetics, safety, tolerability, and immunogenicity of Depemokimab administered via a SSD or autoinjector in healthy participants.
Interventions
- BIOLOGICAL Depemokimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2022-12-13 |
| Est. Completion | 2023-10-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05602025
The ClinicalTrials.gov registry entry for NCT05602025 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Depemokimab is the first listed.
NCT05602025 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05602025 about?
NCT05602025 is a clinical study titled "A Study to Compare the Pharmacokinetics (PK) of Depemokimab When Delivered With a Safety Syringe Device (SSD) or an Autoinjector in Healthy Adult Participants". This study will compare the pharmacokinetics, safety, tolerability, and immunogenicity of Depemokimab administered via a SSD or autoinjector in healthy participants.
What is the current status of trial NCT05602025?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 140 participants. The study started on 2022-12-13. Estimated completion is 2023-10-23.
What interventions are being tested in trial NCT05602025?
The interventions under investigation include: Depemokimab (BIOLOGICAL).
Who is sponsoring clinical trial NCT05602025?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.